Abstract
Numerous placebo-controlled randomized clinical trials have demonstrated the benefit of intravenous glycoprotein (GP) IIb/IIIa inhibitors in percutaneous coronary interventions (PCIs). These agents decrease the incidence of adverse events associated with PCI in various clinical settings (ST-elevation myocardial infarction, acute coronary syndromes, and elective PCI). However, great controversy remains as to whether this benefit is confined to the prevention of small periprocedural myocardial infarctions, because a longer term clinical advantage has not been definitively shown, except with myocardial infarctions comprised of very large (>3 to 5 times normal) enzymatic increases. Nevertheless, all existing clinical trials demonstrate either a small but statistically significant benefit or a trend favoring their use. Meta-analytic methods show that although the degree of the benefit is small, when viewed in the aggregate, it appears convincing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
